The solubility test points, not upper limits, are as follows:
- DMF: 5 mg/ml
- DMSO: 5 mg/ml
- PBS (pH 7.2) (1:6): 0.1 mg/ml
- Ethanol: 3 mg/ml
SML2480
Mirabegron
≥98% (HPLC)
Sinonimo/i:
2-(2-Amino-1,3-thiazol-4-yl)-N-[4-[2-[((2R)-2-hydroxy-2-phenylethyl)amino]ethyl]phenyl]acetamide, 2-Amino-N-[4-[2-[[(2R)-2-hydroxy-2-phenylethyl]amino]ethyl]phenyl]-4-thiazoleacetamide, YM 178, YM178(R)-Mirabegron
Autenticatiper visualizzare i prezzi riservati alla tua organizzazione & contrattuali
Scegli un formato
5 MG
CHF 121.00
25 MG
CHF 482.00
Scegli un formato
Cambia visualizzazione
5 MG
CHF 121.00
25 MG
CHF 482.00
About This Item
Formula empirica (notazione di Hill):
C21H24N4O2S
Numero CAS:
Peso molecolare:
396.51
Numero MDL:
Codice UNSPSC:
12352200
NACRES:
NA.77
Prodotti consigliati
Saggio
≥98% (HPLC)
Stato
powder
Attività ottica
[α]/D -16 to -22°, c = 0.5 in methanol
Colore
white to beige
Solubilità
DMSO: 2 mg/mL, clear
Temperatura di conservazione
2-8°C
Stringa SMILE
O[C@@H](CNCCC1=CC=C(NC(CC2=CSC(N)=N2)=O)C=C1)C3=CC=CC=C3
InChI
1S/C21H24N4O2S/c22-21-25-18(14-28-21)12-20(27)24-17-8-6-15(7-9-17)10-11-23-13-19(26)16-4-2-1-3-5-16/h1-9,14,19,23,26H,10-13H2,(H2,22,25)(H,24,27)/t19-/m0/s1
PBAPPPCECJKMCM-IBGZPJMESA-N
Cerchi prodotti simili? Visita Guida al confronto tra prodotti
Applicazioni
Mirabegron has been used as a β3-adrenergic receptor (β3-AR) agonist in an in vitro experiment to determine whether β3-AR stimulation specifically activates brown adipose tissue (BAT) thermogenesis in humans.
Azioni biochim/fisiol
Mirabegron is a non-antimuscarinic orally active drug with the potential to treat patients with overactive bladder (OAB) symptoms. It aids in bladder relaxation by acting on neural control of the storage phase of micturition by targeting β3-AR. Mirabegron is also used to treat neurogenic detrusor overactivity (NDO) in pediatric patients.
Mirabegron is a potent and selective β3-adrenoceptor agonist that activates the β3 adrenergic receptor in the detrusor muscle in the bladder leading to muscle relaxation and an increase in bladder capacity.
potent and selective β3-adrenoceptor agonist
Avvertenze
Warning
Indicazioni di pericolo
Consigli di prudenza
Classi di pericolo
Repr. 2
Codice della classe di stoccaggio
11 - Combustible Solids
Classe di pericolosità dell'acqua (WGK)
WGK 3
Punto d’infiammabilità (°F)
Not applicable
Punto d’infiammabilità (°C)
Not applicable
Scegli una delle versioni più recenti:
Certificati d'analisi (COA)
Lot/Batch Number
Non trovi la versione di tuo interesse?
Se hai bisogno di una versione specifica, puoi cercare il certificato tramite il numero di lotto.
Possiedi già questo prodotto?
I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.
I clienti hanno visto anche
Toshiyuki Takasu et al.
The Journal of pharmacology and experimental therapeutics, 321(2), 642-647 (2007-02-13)
We evaluated the pharmacological characteristics of (R)-2-(2-aminothiazol-4-yl)-4'-{2-[(2-hydroxy-2-phenylethyl)amino]-ethyl} acetanilide (YM178). YM178 increased cyclic AMP accumulation in Chinese hamster ovary (CHO) cells expressing human beta3-adrenoceptor (AR). The half-maximal effective concentration (EC50) value was 22.4 nM. EC50 values of YM178 for human beta1-
Kentaro Konishi et al.
European journal of drug metabolism and pharmacokinetics, 43(3), 301-309 (2017-11-23)
Mirabegron is cleared by multiple mechanisms, including drug-metabolizing enzymes. One of the most important clearance pathways is direct glucuronidation. In humans, M11 (O-glucuronide), M13 (carbamoyl-glucuronide), and M14 (N-glucuronide) have been identified, of which M11 is one of the major metabolites
Susan J Keam
Paediatric drugs, 23(4), 411-415 (2021-06-01)
Mirabegron (MYRBETRIQ®), a beta-3 adrenergic agonist developed by Astellas Pharma Inc., is well established as a treatment for overactive bladder in adults and is available as extended-release (ER) tablets administered once daily. More recently, mirabegron has been investigated in pediatric
Rebecca Bragg et al.
The Consultant pharmacist : the journal of the American Society of Consultant Pharmacists, 29(12), 823-837 (2014-12-19)
To review the literature regarding the efficacy and safety of mirabegron for the treatment of overactive bladder (OAB). A literature search was performed using MEDLINE (PubMed) prior to December 31, 2013, using the terms "mirabegron" and "randomized-controlled trial." All published
Pradeep Tyagi et al.
Expert opinion on drug safety, 10(2), 287-294 (2010-12-15)
Mirabegron is being developed as a new treatment for the management of overactive bladder (OAB). It is an orally active drug that works by activating the β(3)-adrenoceptor with a better safety profile than antimuscarinic drugs. However, long-term adverse effects are
-
What is the solubility of item SML2480, Mirabegron?
1 answer-
Helpful?
-
Active Filters
Il team dei nostri ricercatori vanta grande esperienza in tutte le aree della ricerca quali Life Science, scienza dei materiali, sintesi chimica, cromatografia, discipline analitiche, ecc..
Contatta l'Assistenza Tecnica.
